Abstract 1054
Background
Second/third-line treatment (Tx) options are limited for pts with NPC. The efficacy and safety of CC-486 were assessed using Simon’s optimal 2-stage design in a phase 2 study. The predefined criterion for advancement to stage 2 (> 4 complete/partial responses) was not met. Here, we present final results from stage 1.
Methods
The single-arm, open-label study (NCT02269943) included pts with locally advanced/metastatic NPC who had ≥ 1 prior Tx, including ≥ 1 platinum-containing regimen. Pts received CC-486 300 mg orally on d 1-14 of a 21-d cycle until disease progression/unacceptable toxicity. The first 6 Asian-Pacific (AP) pts received CC-486 200 mg; if well tolerated, subsequent AP pts received 300 mg. Primary endpoints (per independent reviewer assessment): overall response rate, progression-free survival. Key secondary endpoints: overall survival, disease control rate, safety, pharmacokinetics (PK).
Results
Median age of 36 enrolled pts was 54.0 y. Most were male (81%), had ECOG PS of ≤ 1 (97%), and had ≥ 2 prior systemic anticancer Tx (58%); 36% were AP. Pts received a median of 7.0 Tx cycles; 44% had ≥ 1 dose interruption and 39% had ≥ 1 dose reduction. 22 pts died: 1 on- and 21 post-Tx (> 28 d after last dose); 18 died due to disease complications. The table shows efficacy outcomes. PK analysis showed rapid absorption; exposure was comparable between doses. However, large inter-pt variability and small pt numbers did not allow definitive conclusions. All 36 safety-evaluable pts had ≥ 1 Tx-emergent adverse event (TEAE). Common TEAEs included vomiting (72%) and nausea (67%). Common grade 3/4 TEAEs included neutropenia (33%) and febrile neutropenia (11%).
Conclusions
The safety profile of CC-486 in pts with NPC was consistent with that in other solid tumors and of azacitidine. CC-486 monotherapy did not show sufficient clinical activity in the selected pt population to support further development in these pts.Table: 1071P
| Primary Endpoints | Efficacy-Evaluable Population (n = 25) |
|---|---|
| Overall response rate, n (%) | 3 (12) |
| Partial response | 3 (12) |
| Median progression-free survival (90% CI), mo | 4.7 (3.1 - 7.3) |
| Secondary Endpoints | |
| Disease control rate, n (%) | 13 (52) |
| Median overall survival (90% CI), mo | 18 (14.8 - not reached) |
Clinical trial identification
NCT02269943.
Legal entity responsible for the study
Celgene Corporation.
Funding
Celgene Corporation.
Editorial Acknowledgement
Medical writing assistance was provided by Rebecca Tweedell, PhD, MediTech Media, Ltd, funded by Celgene Corporation. All listed authors were fully responsible for all content and editorial decisions for this abstract.
Disclosure
R. Mesia Nin: Advisory role: AstraZeneca, Merck, MSD, BMS; Conferences fee: BMS, Merck. P. Bossi: Consultant/advisory and/or lectures: AstraZeneca, Kyowa Kyrin, Merck, Mundipharma, Roche; Travel coverage: Merck. L.F. Licitra: Consultant/advisory and/or lectures: AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Debiopharm, Eisai, Merck Serono, MSD, Novartis, Roche, Sobi; Research funds to institution: AstraZeneca, Boehringer Ingelheim, Eisai, Merck Serono, MSD, Novartis, Roche; Travel coverage: Bayer, BMS, Debiopharm, Merck Serono, MSD, Sobi. P. Chen: Employee, stock units and stock options: Celgene. J. Miller: Employee, holds company stock: Celgene Pharmaceutical Company. L.L. Siu: Research funding (to institution): Celgene. R. Haddad: Consulting: BMS, Merck, Pfizer, Celgene, Genentech, AstraZeneca; Research support: BMS, Merck, Pfizer, Genentech, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1978 - FAM115c that upregulates proliferation and invasion under hypoxia could be a predictive biomarker for pancreatic cancer.
Presenter: Kiyoshi Saeki
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3682 - Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3319 - Tumor-infiltrating CD3+ lymphocytes and ICOS+ T-cells predict a favorable survival in resected esophageal squamous cell carcinoma
Presenter: Min Hee Hong
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5130 - Chemokine receptor CXCR7 expression, function and clinical implications in head and neck squamous cell carcinoma
Presenter: Myung-Won Lee
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4483 - Assessment of PD-1/PD-L1 colocalization in hepatocellular carcinoma (HCC) using bright-field double labeling and quantitative digital image analysis
Presenter: Thomas Mrowiec
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1175 - Pulmonary tumor thrombotic microangiopathy (PTTM): 24 case series and its criteria for pathological diagnosis.
Presenter: Naoko Sato
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1359 - Autofluorescence: a new marker for identifying cancer stem cells (CSCs) in primary tumors
Presenter: Miriam López Gómez
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2651 - NACC1 as a target of microRNA-331-3p regulates cell proliferation in urothelial carcinoma cells
Presenter: Kohei Morita
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2233 - Somatic-stem transition of tumor cells is a key link in the metastasis
Presenter: Nicolai Litviakov
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2601 - Profile of individuals who never undergo colorectal cancer screening
Presenter: Jérôme Viguier
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract